Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 14 Oct 2025

The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma

in Cancer Immunity and Immunotherapy

Yue Zhang
Xin Xu
Shuo Li
Chenlong Liao
Xiaosheng Yang
Wenchuan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1660754

724 views

Systematic Review

Accepted on 10 Oct 2025

Navigating the Risks: A systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes

in Cancer Immunity and Immunotherapy

Donghua Liu
Xinyi Wang
Xuelian Liu
Jing Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1689820

195 views

Case Report

Published on 10 Oct 2025

Immune-mediated gastritis in a patient with breast cancer due to therapy with immune checkpoint inhibitor pembrolizumab: a case report

in Cancer Immunity and Immunotherapy

Yalan Xu
Junyao Wang
Ning Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1624185

390 views

Original Research

Published on 10 Oct 2025

Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors

in Cancer Immunity and Immunotherapy

Ruijie Cao
Shasha Zhang
Jingjing Zhang
Yufei Zhao
Xiaoyun Zhang
Zhanjun Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1657332

1,405 views

Original Research

Published on 10 Oct 2025

Dextran sulfate inhibits the invasion, migration, and programmed death-ligand 1 expression in human gastric cancer cells by affecting the M2 tumor-associated macrophage polarization

in Cancer Immunity and Immunotherapy

Jing Shang
Yuanyi Xu
Yuejia Tao
Bing Li
Mengqi Li
Jiaxin Guo
Lvjun Yan
Yunning Huang
Qian Ma

Frontiers in Oncology

doi 10.3389/fonc.2025.1689053

440 views

Systematic Review

Accepted on 09 Oct 2025

The Effect of Traditional Chinese Medicine on Patients Undergoing Targeted Therapy for Liver Cancer: A Systematic Review and Meta-Analysis

in Cancer Immunity and Immunotherapy

Hongting Yan
Yingjie Li
Bin Guo
Bing Yang
Dongxin Tang

Frontiers in Oncology

doi 10.3389/fonc.2025.1674965

121 views

Original Research

Published on 09 Oct 2025

Blood-derived ratio indexes associated with severity and prognosis of immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis

in Cancer Immunity and Immunotherapy

Ling Guo
Zhenli Li
Guangbin Gao
Jing Liu
Zhengkun Guan
Tiezhu Yao
Guang Liu
Qian Jiao
Tenghui Wang
Yansong Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1676806

940 views

Original Research

Published on 09 Oct 2025

Ferroptosis’s Master Switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with in vitro experiments validation

in Cancer Immunity and Immunotherapy

Xiao Li
Min Zhu
Ruihua Dong

Frontiers in Oncology

doi 10.3389/fonc.2025.1643235

595 views

Systematic Review

Published on 08 Oct 2025

The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Qian Feng
Xiaoxia Yan
Liping Gao
Hui Li
Baik Sarah
Russo Anna
Hongying Jiang

Frontiers in Oncology

doi 10.3389/fonc.2025.1657282

422 views

Case Report

Accepted on 07 Oct 2025

Dialysis following sintilimab-induced stage 3 acute kidney injury: Mechanism Investigation and Management Strategies

in Cancer Immunity and Immunotherapy

Bin Shan
Mengjiao Li
Ruixia Yang
Guanqi Wang
Juan Hou
Tianjiao Wen

Frontiers in Oncology

doi 10.3389/fonc.2025.1632740

116 views

Case Report

Published on 07 Oct 2025

Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability

in Cancer Immunity and Immunotherapy

Rong Li
Yan-Ping Lin
Xin Shen
Jiang-Yan Guo
Ya Zhang
Jia-Dai Tang
Lin Xie
Feng-Di Hu

Frontiers in Oncology

doi 10.3389/fonc.2025.1636122

1,150 views

Case Report

Accepted on 06 Oct 2025

Fatal Early-Onset Checkpoint Inhibitor Pneumonitis in a Patient with Advanced Squamous-Cell Lung Cancer with Underlying Pulmonary Fibrosis: A Case Report and Review of the Literature

in Cancer Immunity and Immunotherapy

Daria Keller
Dagobert Żarczyński
Anna Rybacka
Barbara Kuźnar-Kamińska

Frontiers in Oncology

doi 10.3389/fonc.2025.1672093

189 views

Original Research

Published on 06 Oct 2025

Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models

in Cancer Immunity and Immunotherapy

Lauren Cournoyer
Yujia Liu
David B. Jaroch
Tom G. Hullinger
Bryan F. Cox
Steven C. Katz
Jason LaPorte
Ilan B. Layman
Alizee Ballarin
Chandra C. Ghosh

Frontiers in Oncology

doi 10.3389/fonc.2025.1655794

568 views

Case Report

Accepted on 02 Oct 2025

Two cases of immune-associated myocarditis caused by tislelizumab

in Cancer Immunity and Immunotherapy

Jie Zhao
Jinliang Wan
Shan Wang
Shuyue Zhang
Yanzhang Hao

Frontiers in Oncology

doi 10.3389/fonc.2025.1549141

310 views

Brief Research Report

Published on 02 Oct 2025

Evaluating the impact of immune checkpoint inhibitors on liver steatosis and function: a retrospective cohort analysis

in Cancer Immunity and Immunotherapy

Sophie K. Schellhammer
Jessica Quintos Day
Run Fan
Fei Ye
Virginia Planz
Douglas B. Johnson

Frontiers in Oncology

doi 10.3389/fonc.2025.1683982

896 views

Mini Review

Published on 01 Oct 2025

Microbiome-mediated regulation of chemoradiotherapy response

in Cancer Immunity and Immunotherapy

Lan Zhou
Benhua Li
Juan Ren
Shoujin Wang
Jun Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1659467

916 views